CELF2 and acute myeloid leukemia: We found that CELF2 deletion occurred in 9.4% of acute myeloid leukemia (AML) patients (Fig. S1A) and the survival time of AML patients with CELF2 deletion was significantly shorter than that of the others (Fig. S1B).